TITLE:
      Phase 2 Extension Study of Ambrisentan in Pulmonary Arterial Hypertension
SUMMARY:
      AMB-220-E is an international, multicenter, open-label study examining the long-term safety
      of ambrisentan (BSF 208075) in subjects who have previously completed Myogen study
      NCT00046319, "A Phase II, Randomized, Double-Blind, Dose-Controlled, Dose-Ranging,
      Multicenter Study of BSF 208075 Evaluating Exercise Capacity in Subjects with Moderate to
      Severe Pulmonary Arterial Hypertension".
ELIGIBILITY CRITERIA:
      Inclusion Criteria:

          -  Must have completed Visit 14/Week 24 of the NCT00046319 study.

          -  Women of childbearing potential must have a negative urine pregnancy test at the
             Screening/Enrollment Visit and agree to use a reliable double barrier method of
             contraception until study completion and for >=4 weeks following their final study
             visit.

          -  Must have completed the Down-titration Period of NCT00046319 prior to enrollment in
             AMB-220-E and will meet the following additional criteria:

          -  Subjects with a diagnosis of HIV must have stable disease status at the time of
             Screening/Enrollment.

          -  Must be stable on conventional therapy for PAH for >=4 weeks prior to the Screening
             Visit.

        Exclusion Criteria:

          -  Chronic prostanoid therapy, or other investigational prostacyclin derivative within 4
             weeks prior to the Screening Visit.

          -  Intravenous inotrope use within 2 weeks prior to the Screening Visit.

          -  Females who are pregnant or breastfeeding.

          -  Contraindication to treatment with an endothelin receptor antagonist (ERA).
